Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Sets New 12-Month High - Should You Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report)'s share price reached a new 52-week high on Monday . The stock traded as high as $12.13 and last traded at $12.10, with a volume of 21070 shares. The stock had previously closed at $12.00.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Performance

The company's fifty day simple moving average is $10.99 and its two-hundred day simple moving average is $9.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36. The stock has a market capitalization of $27.57 billion, a P/E ratio of 58.76 and a beta of 0.78.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.01. The firm had revenue of $5.92 billion for the quarter, compared to the consensus estimate of $5.41 billion. As a group, equities analysts forecast that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.